Fig. 3: Mouse pharmacokinetics and prophylactic efficacy of CD388 in lethal mouse models of influenza A and B infection.
From: Drug–Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice
a, Plasma levels of CD388 at doses of 0.3–30 mg kg−1 following i.m. administration in mice (mean; n = 2 per group) by NA capture. b, CD388 levels in plasma and lung epithelial lining fluid (ELF) of mice after i.m. dosing (mean ± s.d.; n = 6 per group) by NA capture. c–f, Protection provided by CD388 dosed as indicated i.m. 7 days before lethal challenge against influenza A/Puerto Rico/8/1934 (H1N1) (c), A/Hong Kong/1/1968 (H3N2) (d), B/Florida/4/2006 (Yamagata) (e) and B/Malaysia/2506/2004 (Victoria) (f) in BALB/c mice (n = 5 per group).
